Navigation Links
Alvespimycin in Medical News

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

...osium). Kosan has expanded this Phase 1 trial to include the combination of alvespimycin plus trastuzumab and paclitaxel (Taxol(R)). In the first quarter 2008, Kosan plans to initiate a Phase 2 trial of alvespimycin as monotherapy in patients with HER2-positive metastatic breast cancer who ...

Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...
Alvespimycin in Medical Technology

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

...sion on Monday, June 2, 2008 at 8:00 am to 11 am CT. Abstract 2502, titled, "First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: alvespimycin (A) administered QOD or QD," will be presented at 8:00 to 8:15 am CT in room W375a by Keith Flaherty, M.D., of the University of Pennsylvania. About...

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer

...ients with HER2-positive metastatic breast cancer. alvespimycin has demonstrated the potential to disrupt the acti... to evaluate the safety and anticancer activity of alvespimycin as a single agent in patients who have not previou...ium demonstrated encouraging antitumor activity of alvespimycin in combination with trastuzumab (Herceptin(R)). ...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer. Epothilone...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

...ting in June Phase I Trial Expanding to Include alvespimycin Plus Trastuzumab Plus Pa.... We are expanding the Phase 1 trial to include an alvespimycin plus trastuzumab plus paclitaxel regimen to establ...his year. We believe that the clinical activity of alvespimycin seen in our breast cancer Phase 1 trials to date v...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

...combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

... initiation of our TIME registration program for tanespimycin in patients with multiple myeloma, and with plans underway to advance second- generation alvespimycin into later-stage trials in patients with HER2-positive metastatic breast cancer, we look forward to further characterizing the efficacy and safety pro...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

...apolis, IN, in a poster, titled, "Phase 1 Trial of alvespimycin (KOS-1022; 17-DMAG) and Trastuzumab," at the 2007 ...leadership in the Hsp90 inhibitor area." Phase 1 alvespimycin Results alvespimycin is a second-generation Hsp90 inhibitor that has de...
Alvespimycin in Biological Technology

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

... demonstrated potential activity. -- Kosan will withdraw Hsp90 inhibitor alvespimycin from development in order to commit resources to the development of ta...tabine(R)) and/or Herceptin(R). Kosan plans to discontinue development of alvespimycin in lieu of development of tanespimycin. The process of ending current alves...

Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic and solid tumors and in HER2-positive metastatic breast cancer. Epothilone...

Kosan Announces Third Quarter 2007 Financial Results

...e presentation of updated positive Phase 1 data on alvespimycin in HER2-positive metastatic breast cancer; Phase 1...a Phase 2 monotherapy trial of our Hsp90 inhibitor alvespimycin in newly-diagnosed patients with HER2-positive met...cal trial showing that Kosan's Hsp90 inhibitor alvespimycin demonstrated antitumor activity and tolerabili...

Kosan to Reacquire Epothilone Program From Roche

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan Biosciences to Host Research & Development Day on October 31, 2007

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhib...

Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...

Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference

...trastuzumab (Herceptin(R)), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer. Epothilones inhibi...
Other Tags
(Date:5/22/2015)... 2015 In April 2006, Veatch Consulting ... 9 years they have concentrated their focus to working ... Canada. Because of this growth and their goals to ... in Denver, Colorado, Cleveland, Ohio, Houston, Texas and now ... new dental offices, dental start ups, orthodontic practices, pediatric ...
(Date:5/22/2015)... Bryce Henson, local fitness icon and owner of ... accepted his program’s 100th client. Henson says that reaching ... location evidences the powerful impact his boot camp is ... Camp is the nation’s most popular and fastest growing ... across North America, Europe and Australia. Anaheim Fit Body ...
(Date:5/22/2015)... Yisrayl Hawkins, Pastor and Overseer at The House of ... on religious leaders to make changes in order to achieve ... blog, discusses the history of war, how it started, why ... says mankind was created to lead peaceful, joyful lives, very ... , “Yahweh created mankind, according to His Plan, which is ...
(Date:5/22/2015)... India Network Foundation sponsors various community events ... India. India Network Visitor Health insurance is one ... help hundreds and thousands of families every year. ... by famous playback singer from Mumbai, Smt. Anuradha Paudwal ... Central Florida activities. , Anuradha Paudwal is ...
(Date:5/21/2015)... May 21, 2015 WellCare Health Plans, Inc. ... been selected by the Florida Healthy Kids Corporation (FHKC) to ... of age, as part of the Florida Healthy Kids (FHK) ... 1, 2015, and may be extended for two additional years ... serve children in the FHK program who live in Regions ...
Breaking Medicine News(10 mins):Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2Health News:India Network Visitor Health Insurance Announces Corporate Sponsorship of Anuradha Paudwal Musical in Orlando to Help Fundraise for Hindu Society of Central Florida. 2Health News:WellCare Selected to Continue Participating in the Florida Healthy Kids Program, Will Serve Nine Florida Regions Under the New Contract 2
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
Other Contents